Factor VIII Inhibitor bypassing activity for treatment of bleeding events for hemophilia B patients with inhibitors
General Track – Cycle 2 | DrugsHTA Council Recommendation (as of 29 April 2025)
The HTA Council positively recommends the government financing of Factor VIII Inhibitor bypassing activity for treatment of bleeding events for hemophilia B patients with inhibitors. (See below for more details)
Relevant Information
- Dosage Strengths:
- 500 units/10mL
- 1000 units/20mL
- 2500 units/50mL
- Dosage Form: Powder solution for infusion (IV)
- Status: With Final HTA Council Recommendation
- Topic Assignment: Internal Assessment
- Policy Question: Should Factor VIII Inhibitor bypassing activity for treatment of bleeding events for hemophilia B patients with inhibitors be funded by the government?
- Secretary of Health Decision: Approved for inclusion in the Philippine National Formulary
Evidence and Relevant Documents